Market research
FULC Fulcrum Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 292M
- Analyst target
- 3.5
- Dividend yield
- Not available
- Beta
- 2.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US3596161097
- Market cap
- 292M
- Analyst target
- 3.5
- Dividend yield
- Not available
- Beta
- 2.58
About
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FULC discussion.
5 years, 4 months ago
Fulcrum Therapeutics, Inc is currently in a long term downtrend where the price is trading 12.0% below its 200 day moving average.
From a valuation standpoint, the stock is 97.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.1.
Fulcrum Therapeutics, Inc's total revenue rose by inf% to $4M since the same quarter in the previous year.
Its net income has dropped by 9.9% to $-18M since the same quarter in the previous year.
Finally, its free cash flow fell by 341.0% to $-20M since the same quarter in the previous year.
Based on the above factors, Fulcrum Therapeutics, Inc gets an overall score of 2/5.